BS Medicine Podcast
Hosted by
James McCormack
and
Mike Allan
These podcasts promote healthy skepticism and critical thinking, with the majority presented in a case-based format.
Listen Now
Recommended Listening
Episode 552: A free PREMIUM podcast – HTN and HF
In episode 552, James and Mike go over a couple of new trials. We talk about a blood pressure trial that examined taking the pills in the morning vs the evening and a heart failure trial that looked at getting patients on “high intensity” treatment. Find out the results here. Show notes Cardiovascular outcomes in […]...
Episode 551: Statins in older adults – there is an answer!
In episode 551, James and Mike invite Danielle Perry back to the podcast to talk about the best available evidence for the use of statins in people 65 and over. As you’ll hear, we have lots of evidence so all you need to know is what it says. Then, you can have an evidence-based discussion […]...
Episode 549: Triglyce-Ride that High?
In episode 549, James and Mike invite Blair MacDonald to the podcast for the first time and we talk about a topic that we haven’t really covered to-date. We discuss the evidence around what happens to the risk of pancreatitis when we use triglyceride-lowering medications (fibrates, statins, niacin, omega-3s) in patients with hypertriglyceridemia. Have a […]...
Episode 548: Do you really need to measure lipoprotein(a) or apolipoprotein B
In episode 548, James and Mike invite Betsy Thomas back to the podcast to talk about whether or not measuring lipoprotein(a) or apolipoprotein B improves cardiovascular risk prediction in a meaningful way over and above using standard risk factors. Many guidelines are now recommending we should do these measurements but is this an evidence-based recommendation? […]...
Episode 547: COPD – are the patients in primary care like those in the trials?
In episode 547, James and Mike invite Jessica and Scott back again to talk about whether or not COPD patients seen in primary care are like the people studied in the large COPD trials. We talk about how to focus care on the people who are most likely to benefit from therapy. There are lots […]...
